<DOC>
	<DOCNO>NCT00997191</DOCNO>
	<brief_summary>Intravitreal triamcinolone effective central macular thickness reduction concomitant visual acuity improvement patient diabetic macular edema ( DME ) . VEGF effective inducer permeability , 50.000 time potent histamine , may exert effect retinal vascular permeability alter tight-junctions protein , occlude VE-cadherin . Based principle , rationale anti-VEGF agent treatment increase retinal capillary permeability condition , diabetic macular edema . Therefore , purpose study evaluate effect intravitreal bevacizumab intravitreal triamcinolone associate laser photocoagulation diabetic macular edema .</brief_summary>
	<brief_title>Intravitreal Bevacizumab Triamcinolone Associated Laser Photocoagulation Diabetic Macular Edema ( IBeTA )</brief_title>
	<detailed_description>Macular edema lead cause decrease visual acuity patient diabetic retinopathy1,2 . Laser photocoagulation standard care treatment diabetic macular edema , base ETDRS recent clinical trial findings3,4 . However , visual acuity improvement post-laser observe infrequently , frequent recurrence persistence DME ( refractory DME ) appropriate laser treatment , particularly eye present angiographically diffuse macular edema5-9 , need alternative treatment management DME . In addition , patient significant cataract , precise visualization posterior pole structure may possible , pharmacological therapy intravitreal agent may preferable laser treatment . Recent study show promising result pharmacological therapy Diabetic macular edema . Triamcinolone show similar result compare ranibizumab defer focal/grid LASER pseudophakic eye ( DRCRnet , prompt versus defer ) . Ranibizumab associate defer LASER monotherapy also show promising result ( RISE RIDE ) . However , several concern regard long-term intravitreal injection therapy include economic feasibility public health system , risk endophthalmitis patient acceptability . For reason , present study decide check association LASER drug therapy , attempt improve focal/grid laser outcome reduce number intravitreal injection .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Clinically significant DME biomicroscopic evaluation generalize breakdown inner bloodretina barrier diffuse fluorescein leakage involve foveal center macular area fluorescein angiography Snellen logarithm minimum angle 20/40 bad Central macular thickness great 275 Âµm optical coherence tomography ( OCT ) Glycosylated hemoglobin rate 10 % History glaucoma ocular hypertension Systemic corticoid therapy History thromboembolic event ( include myocardial infarction cerebral vascular accident ) Major surgery within prior 6 month plan within next 28 day Uncontrolled hypertension Severe systemic disease Any condition affect documentation followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Intravitreal</keyword>
	<keyword>Macular edema</keyword>
	<keyword>triamcinolone</keyword>
	<keyword>VEGF</keyword>
</DOC>